Failure of a cytoprotective dose of Arbacet to heal acute gastric ulcers.

Abstract

Twenty outpatients with an endoscopic diagnosis of gastric ulcer were evaluated for 6 wk in a randomized, double-blind trial comparing 15(R)-15-methyl prostaglandin E2 (Arbacet) (10 micrograms, 0.5 h before each meal and at bedtime) with placebo. Endoscopy was performed at 3 wk and 6 wk during the study period. Five of nine patients (56%) taking Arbacet and seven of 11 patients (64%) in the placebo group had complete healing of their gastric ulcer. Healing occurred in four patients from the Arbacet group and three patients in the placebo group at 3 wk. A cytoprotective dose of Arbacet (40 micrograms daily) is not significantly better than placebo in healing gastric ulcers.

• Authors: R Jaszewski, S A Crane
• Journal: The American journal of gastroenterology (Am J Gastroenterol) Vol. 83 Issue 7 Pg. 734-6 (Jul 1988) ISSN: 0002-9270 [Print] United States
• PMID: 3289379 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Placebos
• Prostaglandins E, Synthetic
• Arbaprostil

Topics

• Acute Disease
• Arbaprostil (administration & dosage, therapeutic use)
• Clinical Trials as Topic
• Double-Blind Method
• Female
• Gastroscopy
• Humans
• Male
• Middle Aged
• Placebos
• Prostaglandins E, Synthetic (therapeutic use)
• Random Allocation
• Stomach Ulcer (drug therapy, pathology, physiopathology)